In 2016 the Office of the Inspector General (OIG) will determine the extent to which FDA requires postmarketing studies and clinical trials (referred to as
OIG-Workplan-2016“postmarketing requirements,” or PMRs) for new drug applications. We will also assess how FDA monitors PMRs and takes enforcement action against applicants that do not comply with them. Section 505(o)(3) of the Food and Drug Administration Amendments Act of 2007 (FDAAA) provides FDA new authority to require additional testing of an approved prescription drug or biological product to assess serious risk related to its use. Under this authority, FDA may require an applicant to conduct PMRs at the time of approval or after approval if FDA becomes aware of new safety information or an unexpected serious risk associated with the use of the drug. (OEI; 01-14- 00390; expected issue date: FY 2016)
[Read more…]
NB: Refer to page 56